Adult Growth Hormone Deficiency (AGHD) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

March 05 14:50 2021
Adult Growth Hormone Deficiency (AGHD) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Adult Growth Hormone Deficiency (AGHD) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Adult Growth Hormone Deficiency (AGHD), historical and forecasted epidemiology as well as the Adult Growth Hormone Deficiency (AGHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Adult-Onset Growth Hormone Deficiency (AGHD) is a medical condition that occurs when the body does not produce enough growth hormone. It stimulates the release of another hormone called insulin-like growth factor 1, which is produced mainly by the liver. Together, these hormones produce growth in childhood and, in adult life, have widespread metabolic effects throughout the body.

Adults with GHD fall into two categories which include: childhood-onset (GHD began during childhood and has continued) and Adult-onset (GHD developed after reaching adulthood). GHD in adults is associated with premature mortality, increased adiposity or fat mass, as well as psychiatric-cognitive, cardiovascular, muscular, metabolic, and skeletal abnormalities.

Get FREE sample copy at: 
https://www.delveinsight.com/sample-request/adult-growth-hormone-deficiency-aghd-market

The Adult Growth Hormone Deficiency (AGHD) market report also covers emerging drugs, current treatment practices, Adult Growth Hormone Deficiency (AGHD) market share of the individual therapies, current and forecasted Adult Growth Hormone Deficiency (AGHD) Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Adult Growth Hormone Deficiency (AGHD) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

 Adult Growth Hormone Deficiency (AGHD) Market

Adult Growth Hormone Deficiency (AGHD) Market Key Facts

  • According to D B Allen et al., about 15%-20% of the cases represent the transition of childhood GH deficiency into adulthood.

  • As per Jana Bujanova et al., the estimated prevalence of AGHD in the UK is approximately 1 in 10 000 (a total of approximately 6380 patients). If Childhood-onset GH deficiency is added to this number then prevalence is 1 in 10 000 to 1 in 3500.

  • According to Growth hormone Foundation estimates, more than 50,000 adults in the United States are growth hormone deficient, and 6,000 new cases are reported each year, including GHD children who transition to GHD as an adult.

  • As per London Endocrine Center, for adult-onset GHD, indirect estimates based on the Prevalence of pituitary gland tumors suggest a Prevalence of 10 cases per million people annually. In the UK, the exact prevalence of GHD is unknown but estimated to be approximately 3 per 10,000 equating to 15,000 adults.

  • According to the study conducted by Akira Shimatsu et al., a greater proportion (80%) of Japanese adults had adult-onset GHD than childhood-onset GHD.

Key Benefits of Adult Growth Hormone Deficiency (AGHD) Market Report

  • Adult Growth Hormone Deficiency (AGHD) market report provides an in-depth analysis of Adult Growth Hormone Deficiency (AGHD) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The Adult Growth Hormone Deficiency (AGHD) market report will help in developing business strategies by understanding the Adult Growth Hormone Deficiency (AGHD) Market trends & developments, key players, and future market competition that will shape and drive the Adult Growth Hormone Deficiency (AGHD) market in the upcoming years.

  • The Adult Growth Hormone Deficiency (AGHD) market report covers Adult Growth Hormone Deficiency (AGHD) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Adult Growth Hormone Deficiency (AGHD) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Adult Growth Hormone Deficiency (AGHD) Market

Adult Growth Hormone Deficiency (AGHD) market size is expected to increase during the forecast period owing to the extensive R&D activities by academics and companies and the rise in the number of Prevalent cases of Adult growth hormone deficiency patients in 7MM.

The Adult Growth Hormone Deficiency (AGHD) market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Adult Growth Hormone Deficiency (AGHD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Adult Growth Hormone Deficiency (AGHD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Adult Growth Hormone Deficiency (AGHD) Epidemiology

The Adult Growth Hormone Deficiency (AGHD) epidemiology section covers insights about the historical and current Adult Growth Hormone Deficiency (AGHD) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Adult Growth Hormone Deficiency (AGHD) Drugs Uptake and Key Market Players

The Adult Growth Hormone Deficiency (AGHD) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adult Growth Hormone Deficiency (AGHD) market or expected to get launched in the market during the study period. The analysis covers Adult Growth Hormone Deficiency (AGHD) market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of the Adult growth hormone deficiency market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world & the launch of emerging therapies during the forecast period.

Adult Growth Hormone Deficiency (AGHD) Companies:
Ascendis Pharma
Genexine
OPKO Health
Novo Nordisk
And many others.

Adult Growth Hormone Deficiency (AGHD) therapies covered in the report include:
TransCon hGH
HyTropin
Somatrogon
Norditropin
And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Adult Growth Hormone Deficiency (AGHD) Competitive Intelligence Analysis

4. Adult Growth Hormone Deficiency (AGHD) Market Overview at a Glance

5. Adult Growth Hormone Deficiency (AGHD) Disease Background and Overview

6. Adult Growth Hormone Deficiency (AGHD) Patient Journey

7. Adult Growth Hormone Deficiency (AGHD) Epidemiology and Patient Population

8. Adult Growth Hormone Deficiency (AGHD) Treatment Algorithm, Current Treatment, and Medical Practices

9. Adult Growth Hormone Deficiency (AGHD) Unmet Needs

10. Key Endpoints of Adult Growth Hormone Deficiency (AGHD) Treatment

11. Adult Growth Hormone Deficiency (AGHD) Marketed Products

12. Adult Growth Hormone Deficiency (AGHD) Emerging Therapies

13. Adult Growth Hormone Deficiency (AGHD) Seven Major Market Analysis

14. Attribute Analysis

15. Adult Growth Hormone Deficiency (AGHD) Market Outlook (7 major markets)

16. Adult Growth Hormone Deficiency (AGHD) Access and Reimbursement Overview

17. KOL Views on the Adult Growth Hormone Deficiency (AGHD) Market.

18. Adult Growth Hormone Deficiency (AGHD) Market Drivers

19. Adult Growth Hormone Deficiency (AGHD) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Related Reports
Adult Growth Hormone Deficiency (AGHD) Pipeline Insights
Adult Growth Hormone Deficiency (AGHD) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Adult Growth Hormone Deficiency (AGHD) market.

BioPharma Blog – Chronic Hepatitis B Therapeutics Market

 About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/dimapurnewsdesk/delhi-today.com/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7